The activists have called out the FDA for giving Gilead Sciences, who have been repeatedly accused of price gouging, a monopoly on a possible COVID-19 treatment.
The program could also cost uninsured people up to $1,000 per year.
It will be housed in an Oakland warehouse.
Experts say, however, there’s no reason to panic.
Advocates have discovered that the drugmaker never sought exclusivity for manufacturing Truvada.
“If the plan does not explicitly address the unique needs of these populations, it will fail,” says Raniyah Copeland, president of the Black AIDS Institute.
The Viva Glam campaign is looking to its next 25 years.